By Fineline Cube 
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial shipments of its next-generation anti-VEGF drug, Beovu (brolucizumab injection), for the treatment of diabetic macular edema (DME). The first prescriptions were written across various locations nationwide.
Drug Profile
Beovu stands out as the world’s first single-chain antibody approved for ophthalmic use. Its innovative design features an ultra-small molecular size of 26 kDa, a high-concentration formulation, and precise targeting of VEGF-A. These attributes position Beovu to address significant challenges in current DME treatment, including inadequate fluid control and poor compliance due to frequent injections.
Clinical Advantages
By offering a treatment model with longer intervals between injections, faster onset of action, and superior efficacy, Beovu is expected to transform the DME treatment landscape. This advancement underscores Novartis’ commitment to enhancing patient outcomes and quality of life for those affected by DME.-Fineline Info & Tech